MAPT and Alzheimer disease: In line with data reported by most studies [10–12, 16–20, 26], we found that plasma NDEV levels of Aβ42, total-tau, P-T181-tau, and P-S393-tau are higher and those of NRGN and REST lower in patients with mild-to-moderate AD than in control subjects (Fig. 1a–f).